QUAZAR AML-001 Multivariate Analysis: Predictors of Survival Outcomes With Oral Azacitidine (CC-486) Among Patients With AML in Remission After Intensive Chemotherapy

June 4-8, 2021; Online at https://conferences.asco.org/am
Cytogenetic risk and MRD status identified as independent predictors of overall survival and relapse-free survival with oral azacytidine in this multivariate analysis.
Format: Microsoft PowerPoint (.ppt)
File Size: 455 KB
Released: June 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Related Content

Analysis of key studies in hematologic malignancies from ASCO 2021 presented by Drs. Ian Flinn, Shaji Kumar, and Eunice Wang, as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji K. Kumar, MD Eunice S. Wang, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 13, 2021 Expired: September 12, 2022

Gain key clinical insights from Sagar Lonial, MD on anti-BCMA ADCs for R/R MM, from Clinical Care Options (CCO)

Sagar Lonial, MD Released: September 10, 2021

Gain key clinical insights from Suzanne Lentzsch, MD, PhD on anti-BCMA bispecific antibodies for R/R MM, from Clinical Care Options (CCO)

Suzanne Lentzsch, MD, PhD Released: September 10, 2021

Gain key clinical insights from Thomas G. Martin, MD on anti-BCMA CAR T-cell therapy for R/R MM, from Clinical Care Options (CCO)

Thomas G. Martin, MD Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue